Release Date: August 15, 2025

Expiration Date: August 15, 2026

Activity Overview

TROP2 is an actionable target in the treatment of triple-negative breast cancer (TNBC) owing to its high expression on tumor cells and low expression on healthy tissue. TROP2-targeting antibody-drug conjugates (ADCs) deliver potent cytotoxic chemotherapy to cancer cells. In this activity, two experts in TNBC management dissect clinical trial and real-world data for ADCs used to treat TNBC.

Target Audience

This activity is directed toward medical oncologists, APPs, nurses, pharmacists, and other HCPs who manage patients with breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Develop evidence-based strategies for integrating ADCs in the management of patients with metastatic TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

GET STARTED WITH THIS PROGRAM:

Related Content